Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

i3 Health

New Thinking, New Strategies in the Treatment of Advanced NSCLC Without Driver Mutations

Access Activity

Overview / Abstract:

STATEMENT OF NEED

Of the estimated 228,150 patients diagnosed with lung cancer in the United States each year, 84% have non-small cell lung cancer (NSCLC). Most patients with NSCLC present with advanced disease, which is highly resistant to chemotherapy. The 5-year survival rates remain dismal (18%). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. However, a number of targeted treatments are not applicable to patients without driver mutations. For such patients, treatment after first-line platinum-based chemotherapy involves immunotherapies targeting the PD-1/PD-L1 pathways; antiangiogenic agents have also shown promise. The use of immunotherapies (eg, checkpoint inhibitors) makes molecular testing essential to guiding clinical management. Whereas several studies have demonstrated that tumor mutation burden has been associated with checkpoint inhibitor efficacy, uptake in testing for this biomarker is limited. The bleak survival rates for NSCLC also indicate a need for continued development of more effective approaches to tumor control.

TARGET AUDIENCE

Oncology physicians, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1. Assess molecular and clinical factors that can refine personalized care plans for patients with advanced NSCLC without driver mutations
2. Evaluate efficacy and safety data on first- and second-line treatment strategies for patients with advanced NSCLC without driver mutations
3. Discuss the rationale supporting angiogenesis as a therapeutic target in advanced NSCLC

Expiration

Sep 11, 2020

Discipline(s)

Physician CME, Physician Assistant CME

Format

Online, Webinar / Webcast / Video

Credits / Hours

1.0

Accreditation

ACCME

Presenters / Authors / Faculty

Jamie E. Chaft, MD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center

Sponsors / Supporters / Grant Providers

This activity is supported by an independent educational grant from Lilly.

Keywords / Search Terms

i3 Health i3 Health, NSCLC, lung cancer, non-small cell lung cancer, cancer, oncology, immunotherapy, molecular biomarkers, targeted therapy, free CME, CME, ILNA points Free CE CME

Access Activity

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.